aod9604 clinical trials weight loss efficacy AOD-9604 vs MOTS-c vs Tesamorelin vs Semaglutide vs Tirzepatide Understanding AOD 9604: The Science

This enhanced scrutiny helps paint a clearer, more granular picture of its effects

Rarely, a developing fetus with preexisting liver disease can develop neonatal hemochromatosis

Possible side effects include injection-site discomfort, mild redness, or temporary GI symptoms

Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7